The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Bian, Nannan; Shi, Xinyu; Qi, Hongyu; Hu, Xin; Ge, Yang; An, Guangyu; Feng, Guosheng

doi:10.1097/md.0000000000016764

Cited by 13 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Squamous cell carcinoma-associated antigen (SCC-Ag) is one of the serine protease inhibitor family of endogenous serine protease inhibitors, mainly existing in the cytoplasm of squamous cell carcinoma of the lung, uterus, esophagus, etc. A high level of SCC-Ag is usually associated with poorly differentiated and advanced metastatic squamous cell carcinoma [ 63 ]. Wen et al [ 6 ] indicated that EGFR mutation was more common in NSCLC patients whose SCC-Ag level is under 1.5 ng/mL.…”

Section: Serum Tumor Markersmentioning

confidence: 99%

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

Liu

Xiong

2021

Current Oncology

View full text Add to dashboard Cite

Lung cancer ranks first in the incidence and mortality of cancer in the world, of which more than 80% are non-small cell lung cancer (NSCLC). The majority of NSCLC patients are in stage IIIB~IV when they are admitted to hospital and have no opportunity for surgery. Compared with traditional chemotherapy, specific targeted therapy has a higher selectivity and fewer adverse reactions, providing a new treatment direction for advanced NSCLC patients. Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are the widely used targeted therapy for NSCLC patients. Their efficacy and prognosis are closely related to the mutation status of the EGFR gene. Clinically, detecting EGFR gene mutation is often limited by difficulty obtaining tissue specimens, limited detecting technology, and economic conditions, so it is of great clinical significance to find indicators to predict EGFR gene mutation status. Clinicopathological characteristics, tumor markers, liquid biopsy, and other predictors are less invasive, economical, and easier to obtain. They can be monitored in real-time, which is supposed to predict EGFR mutation status and provide guidance for the accurate, individualized diagnosis and therapy of NSCLC patients. This article reviewed the correlation between the clinical indicators and EGFR gene mutation status in NSCLC patients.

show abstract

Section: Serum Tumor Markersmentioning

confidence: 99%

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

Liu

Xiong

2021

Current Oncology

View full text Add to dashboard Cite

show abstract

“…It is currently believed that besides factors like genetics and social influence, immune escape mechanisms are also crucial in LC's presence and advancement [ 1 ]. Relevant studies have pointed out when the patient's immunity is reduced or suppressed, the tumor progression rate is memorably accelerated [ 2 ]. Hence, immunotherapy, as a novel kind of adjuvant cure for cancer patients, has been gradually applied to the clinic.…”

Section: Introductionmentioning

confidence: 99%

Changes of Tumor Markers in Patients with Lung Cancer after Immunotherapy and Their Link with Inflammation in the Body

Liu¹,

Cai²,

Tao³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Purpose. To figure out tumor markers changes in lung cancer (LC) patients after immunotherapy and their link with inflammation in the body. Methods. From May 2017 to January 2021, taking 97 LC patients with elevated Programmed Cell Death Protein 1 and Programmed Cell Death Protein-ligand 1 was as the research objects. They were all given immunotherapy and assigned into the remission and the nonremission groups on the grounds of the tumor remission after 6 months of treatment, after comparison of tumor markers [carcinoembryonic antigen (CEA), squamous cell carcinoma-associated antigen (SCC-Ag), cytokeratin 19 fragment (CYFRA12-1), and neuron-specific enolase (NSE)] and inflammation indicators [interleukin-10 (IL-10), interleukin (IL-6), and tumor necrosis factor-α (TNF-α)] in the two. Results. Tumor markers, IL-10, IL-6, and TNF-α in the remission after treatment were reduced vs. the nonremission ( P < 0.05 ); SCC-Ag was positively linked with IL-10, IL-6, and TNF-α in the patients after treatment ( P < 0.05 ); the AUC of the combined detection to assess the efficacy of LC immunotherapy was greater vs. the individual detection of indicators ( P < 0.05 ). Conclusion. Tumor markers and the inflammation state of the body in LC patients are memorably reduced after immunotherapy, and a correlation is presented between the two, which manifests evaluating value of the efficacy of immunotherapy.

show abstract

“…Apart from being a diagnostic marker for activation of coagulation and brinolysis, D-dimer also played an important role in cancer progression, invasion, and prognosis [29]. Recent research showed that activation of the coagulation system was associated with tumorigenesis development, dissemination and transfer [31,32]. Fibrinolytic enzymes in brinolytic systems played an important role in tumor invasion and penetration into the blood circulation.…”

Section: Patient Characteristicsmentioning

confidence: 99%

The prognostic value of CA19-9, D-dimer and expression of TNFAIP3(A20) protein in pancreatic ductal adenocarcinoma patients

Xu¹,

Dx²,

Nz³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To explore significance of CA19-9, D-dimer with TNFAIP3 (A20) protein and evaluate its prognostic signiﬁcance in patients suffering from pancreatic ductal adenocarcinoma (PDAC). Methods: 148 patients suffering from pancreatic ductal adenocarcinoma in Northern Jiangsu People’s Hospital affiliated to Yangzhou University between January 2012 to December 2016 were studied. Cutoff values of prognostic factors were predicted by Receiver operating characteristic curve (ROC curve). Kaplan-Meier method was used to describe survival curve of patients. Univariate and multivariate regression analyses were used to analyze prognostic factors of patients. Results: The recommended cutoff values of the neutrophil-lymphocyte rate (NLR), platelet-lymphocyte rate (PLR), CA19-9 and D-dimer were 2.04 (sensitivity, 0.59; specificity, 0.9; area under the ROC curve (AUC), 0.749; P<0.001), 52.94 (sensitivity, 0.73; specificity, 0.95; AUC, 0.829; P<0.001), 176.66U/ml (sensitivity, 0.7; specificity, 0.9; AUC, 0.794; P<0.001) and 1.18mg/L (sensitivity, 0.82; specificity, 0.9; AUC, 0.845; P<0.001) respectively. The expression of CA19-9 in serum was related with lymph node metastasis (P = 0.010), tumor lymph node metastasis (TNM) stage (P <0.001) and survival ratio (P <0.001). The D-dimer was positively related with differentiation grade (P=0.014), tumor size (P=0.045), TNM stage (P=0.006) and survival ratio (P<0.001). A20 was positively related with differentiation grade (P<0.001), BMI (P<0.001), TNM stage (P=0.024) and survival ratio (P<0.001). The Kaplan-Meier curves showed that the patients with pancreatic ductal adenocarcinoma had a significant difference in the expression of CA19-9 group, expression of D-dimer group and expression of A20 (P<0.05). CA19-9, D-dimer, TNM stage, differentiation grade and A20 were independent prognostic markers for patients sufferingfrom pancreatic ductal adenocarcinoma by univariate and COX multivariate analyses. Conclusions: CA19-9, D-dimer and A20 were independent prognostic markers for pancreatic ductal adenocarcinoma patients.

show abstract

The relationship of plasma fibrinogen with clinicopathological stages and tumor markers in patients with non-small cell lung cancer

Cited by 13 publications

References 37 publications

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

Changes of Tumor Markers in Patients with Lung Cancer after Immunotherapy and Their Link with Inflammation in the Body

The prognostic value of CA19-9, D-dimer and expression of TNFAIP3(A20) protein in pancreatic ductal adenocarcinoma patients

Contact Info

Product

Resources

About